A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Latest Information Update: 25 Nov 2021
At a glance
- Drugs Human papillomavirus vaccine (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors National Vaccine & Serum Institute
Most Recent Events
- 23 Nov 2021 Status changed from active, no longer recruiting to completed.
- 25 Aug 2021 Planned End Date changed from 12 Jul 2021 to 12 Oct 2021.
- 25 Aug 2021 Planned primary completion date changed from 12 Jul 2021 to 12 Oct 2021.